190 related articles for article (PubMed ID: 35568919)
1. Nanotechnological engineering of extracellular vesicles for the development of actively targeted hybrid nanodevices.
Dumontel B; Susa F; Limongi T; Vighetto V; Debellis D; Canta M; Cauda V
Cell Biosci; 2022 May; 12(1):61. PubMed ID: 35568919
[TBL] [Abstract][Full Text] [Related]
2. Anti-CD38 targeted nanotrojan horses stimulated by acoustic waves as therapeutic nanotools selectively against Burkitt's lymphoma cells.
Vighetto V; Conte M; Rosso G; Carofiglio M; Sidoti Abate F; Racca L; Mesiano G; Cauda V
Discov Nano; 2024 Feb; 19(1):28. PubMed ID: 38353903
[TBL] [Abstract][Full Text] [Related]
3. Extracellular Vesicles Tropism: A Comparative Study between Passive Innate Tropism and the Active Engineered Targeting Capability of Lymphocyte-Derived EVs.
Limongi T; Susa F; Dumontel B; Racca L; Perrone Donnorso M; Debellis D; Cauda V
Membranes (Basel); 2021 Nov; 11(11):. PubMed ID: 34832115
[TBL] [Abstract][Full Text] [Related]
4. ZnO nanocrystals shuttled by extracellular vesicles as effective Trojan nano-horses against cancer cells.
Dumontel B; Susa F; Limongi T; Canta M; Racca L; Chiodoni A; Garino N; Chiabotto G; Centomo ML; Pignochino Y; Cauda V
Nanomedicine (Lond); 2019 Nov; 14(21):2815-2833. PubMed ID: 31747855
[No Abstract] [Full Text] [Related]
5. Zinc Oxide Nanocrystals and High-Energy Shock Waves: A New Synergy for the Treatment of Cancer Cells.
Racca L; Limongi T; Vighetto V; Dumontel B; Ancona A; Canta M; Canavese G; Garino N; Cauda V
Front Bioeng Biotechnol; 2020; 8():577. PubMed ID: 32582682
[TBL] [Abstract][Full Text] [Related]
6. Preclinical studies of targeted therapies for CD20-positive B lymphoid malignancies by Ofatumumab conjugated with auristatin.
Li ZH; Zhang Q; Wang HB; Zhang YN; Ding D; Pan LQ; Miao D; Xu S; Zhang C; Luo PH; Naranmandura H; Chen SQ
Invest New Drugs; 2014 Feb; 32(1):75-86. PubMed ID: 23903896
[TBL] [Abstract][Full Text] [Related]
7. γδ T-cell killing of primary follicular lymphoma cells is dramatically potentiated by GA101, a type II glycoengineered anti-CD20 monoclonal antibody.
Braza MS; Klein B; Fiol G; Rossi JF
Haematologica; 2011 Mar; 96(3):400-7. PubMed ID: 21109686
[TBL] [Abstract][Full Text] [Related]
8. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
Plosker GL; Figgitt DP
Drugs; 2003; 63(8):803-43. PubMed ID: 12662126
[TBL] [Abstract][Full Text] [Related]
9. CD20 antibody (C2B8)-induced apoptosis of lymphoma cells promotes phagocytosis by dendritic cells and cross-priming of CD8+ cytotoxic T cells.
Selenko N; Maidic O; Draxier S; Berer A; Jäger U; Knapp W; Stöckl J
Leukemia; 2001 Oct; 15(10):1619-26. PubMed ID: 11587221
[TBL] [Abstract][Full Text] [Related]
10. CD20 monoclonal antibody targeted nanoscale drug delivery system for doxorubicin chemotherapy: an in vitro study of cell lysis of CD20-positive Raji cells.
Jiang S; Wang X; Zhang Z; Sun L; Pu Y; Yao H; Li J; Liu Y; Zhang Y; Zhang W
Int J Nanomedicine; 2016; 11():5505-5518. PubMed ID: 27843311
[TBL] [Abstract][Full Text] [Related]
11. Differential tumor cell targeting of anti-HER2 (Herceptin) and anti-CD20 (Mabthera) coupled nanoparticles.
Cirstoiu-Hapca A; Bossy-Nobs L; Buchegger F; Gurny R; Delie F
Int J Pharm; 2007 Mar; 331(2):190-6. PubMed ID: 17196347
[TBL] [Abstract][Full Text] [Related]
12. The Enhanced Cytotoxic Effects in B-Cell Leukemia and Lymphoma Following Activation of Prostaglandin EP4 Receptor and Targeting of CD20 Antigen by Monoclonal Antibodies.
Markovič T; Podgornik H; Avsec D; Nabergoj S; Mlinarič-Raščan I
Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35163524
[TBL] [Abstract][Full Text] [Related]
13. Targeted delivery of interferon-alpha via fusion to anti-CD20 results in potent antitumor activity against B-cell lymphoma.
Xuan C; Steward KK; Timmerman JM; Morrison SL
Blood; 2010 Apr; 115(14):2864-71. PubMed ID: 20139095
[TBL] [Abstract][Full Text] [Related]
14. Development of an SPR-based binding assay for characterization of anti-CD20 antibodies to CD20 expressed on extracellular vesicles.
Wang X; Phan MM; Sun Y; Koerber JT; Ho H; Chen Y; Yang J
Anal Biochem; 2022 Jun; 646():114635. PubMed ID: 35278435
[TBL] [Abstract][Full Text] [Related]
15. Cellular immunotherapy for follicular lymphoma using genetically modified CD20-specific CD8+ cytotoxic T lymphocytes.
Wang J; Press OW; Lindgren CG; Greenberg P; Riddell S; Qian X; Laugen C; Raubitschek A; Forman SJ; Jensen MC
Mol Ther; 2004 Apr; 9(4):577-86. PubMed ID: 15093188
[TBL] [Abstract][Full Text] [Related]
16. Construction and characterization of monoclonal antibodies against the extracellular domain of B-lymphocyte antigen CD20 using DNA immunization method.
Khademi F; Mostafaie A; Parvaneh S; Gholami Rad F; Mohammadi P; Bahrami G
Int Immunopharmacol; 2017 Feb; 43():23-32. PubMed ID: 27939822
[TBL] [Abstract][Full Text] [Related]
17. Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity.
Mössner E; Brünker P; Moser S; Püntener U; Schmidt C; Herter S; Grau R; Gerdes C; Nopora A; van Puijenbroek E; Ferrara C; Sondermann P; Jäger C; Strein P; Fertig G; Friess T; Schüll C; Bauer S; Dal Porto J; Del Nagro C; Dabbagh K; Dyer MJ; Poppema S; Klein C; Umaña P
Blood; 2010 Jun; 115(22):4393-402. PubMed ID: 20194898
[TBL] [Abstract][Full Text] [Related]
18. Generation of CD20-specific TCRs for TCR gene therapy of CD20low B-cell malignancies insusceptible to CD20-targeting antibodies.
Jahn L; van der Steen DM; Hagedoorn RS; Hombrink P; Kester MG; Schoonakker MP; de Ridder D; van Veelen PA; Falkenburg JH; Heemskerk MH
Oncotarget; 2016 Nov; 7(47):77021-77037. PubMed ID: 27776339
[TBL] [Abstract][Full Text] [Related]
19. Engineered CD20-specific primary human cytotoxic T lymphocytes for targeting B-cell malignancy.
Jensen MC; Cooper LJ; Wu AM; Forman SJ; Raubitschek A
Cytotherapy; 2003; 5(2):131-8. PubMed ID: 12745575
[TBL] [Abstract][Full Text] [Related]
20. Complement-Dependent Activity of CD20-Specific IgG Correlates With Bivalent Antigen Binding and C1q Binding Strength.
Bondza S; Marosan A; Kara S; Lösing J; Peipp M; Nimmerjahn F; Buijs J; Lux A
Front Immunol; 2020; 11():609941. PubMed ID: 33505398
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
